Comparison of the potency of newly developed and currently available oximes to reactivate nerve agent-inhibited acetylcholinesterase in vitro and in vivo

Department of Toxicology, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic.
Chemico-Biological Interactions (Impact Factor: 2.58). 01/2006; 157-158:367-8. DOI: 10.1016/j.cbi.2005.10.054
Source: PubMed


Reactivation potency of three newly developed oximes K027, K033 and K048 was tested using standard in vitro and in vivo reactivation tests. K027 and K048 seem to be efficacious reactivators of tabun-inhibited acetylcholinesterase. K033 is sufficient reactivator of cyclosarin-inhibited AChE. However, its potency is poor compared with current "gold standard" oxime HI-6.

1 Follower
6 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this paper we give a tutorial account of several of the most recent adaptive control results for rigid robot manipulators. Our intent is to lend some perspective to the growing list of adaptive control results for manipulators by providing a unified framework for comparison of those adaptive control algorithms which have been shown to be globally convergent. In most cases we are able to simplify the derivations and proofs of these results as well.
    No preview · Article · Jan 1988 · Automatica
  • [Show abstract] [Hide abstract]
    ABSTRACT: The problems of a plane wave scattering from a multilayered resistive strip grating embedded in a dielectric slab without and with an impedance plane and a multilayered perpendicularly crossed resistive strip grating in free space have been analyzed in order to investigate the absorption and scattering characteristics of resistive gratings. Each of considered problems is converted into a set of integral equations, which were solved by the moment method with appropriate basis functions to ensure a fast convergence. It has been verified that the obtained solutions are very efficient over a broad range of parameters of the incident wave and considered gratings
    No preview · Conference Paper · Feb 2001
  • [Show abstract] [Hide abstract]
    ABSTRACT: The traditional therapeutic treatment of organophosphate cholinesterase inhibitor (nerve agents) poisoning consists of co-treatment with an antimuscarinic (atropine) and a reactivator of inhibited acetylcholinesterase (AChE), which contains a nucleophilic oxime function. Two oximes are presently widely available for clinical use, pralidoxime and obidoxime (toxogonin), but both offer little protection against important nerve agent threats. This has highlighted the real need for the development and availability of more effective oximes for human use, a search that has been going on for up to 30 years. However, despite the demonstration of more effective and safe oximes in animal experiments, no additional oximes have been licensed for human use. HI-6, (1-[[[4(aminocarbonyl)-pyridinio]methoxy]methyl]-2(hydroxyimino)pyridinium dichloride; CAS 34433-31-3) has been studied intensively and has been proved effective in a variety of species including non-human primates and appears from clinical experience to be safe in humans. These studies have led to the fielding of HI-6 for use against nerve agents by the militaries of the Czech republic, Sweden, Canada and under certain circumstances the Organisation for the Prohibition of Chemical Weapons. Nevertheless HI-6 has not been granted a license for clinical use, must be used only under restricted guidelines and is not available for civilian use as far as is known. This article will highlight those factors relating to HI-6 that pertain to the licensing of new compounds of this type, including the mechanism of action, the clinical and pre-clinical demonstration of safety and its efficacy against a variety of nerve agents particularly in non-human primates, since no relevant human population exists. This article also contains important data on the use of HI-6 in baboons, which has not been available previously. The article also discusses the possibility of successful therapy with HI-6 against poisoning in humans relative to doses used in non-human primates and relative to its ability to reactivate inhibited human AChE.
    No preview · Article · Feb 2006 · Toxicological Reviews
Show more